Global R＆D Network
Centering our R&D activities in Japan and the United States, our global R&D network connects Japan, the United States, Europe, and East Asian countries. Our strong cross-functional global R&D network is built based on our people’s initiatives and collaboration with the shared purpose: “For Patients ”.
Shinagawa R&D Center, Tokyo
Shinagawa R&D Center has created various innovative new medicines over the years as the center of research and development of Daiichi Sankyo and delivered them to medical sites and patients. We are promoting drug discovery research, non-clinical research, and translational research, with the aim of promoting disease research with cutting-edge science and technology and creating innovative pharmaceuticals through the Multi-modality strategy. We are also promoting global clinical development collaboratively working with Daiichi Sankyo Pharma Development in USA and related divisions of such as biologics, pharmaceutical technology, and quality assurance. Furthermore, it promotes clinical trials seamlessly with the development department of Daiichi Sankyo RD Novare, and also plays the role of supervising the development department of East Asia's group companies as a clinical development base in the East region.
Kasai R&D Center, Tokyo
Kasai RD Center leads safety research and vaccine research, and Daiichi Sankyo RD Novare promotes drug discovery research on a state-of-the-art technology platform for non-clinical research and a translational research platform centered on a clinical sample analysis facility.
Tatebayashi Biopharmaceuticals Center, Gunma prefecture
Tatebayashi Biopharmaceuticals Center is leading research in the development of biopharmacy manufacturing processes that require advanced technology and makes sure high-quality biopharmacy can stably delivered to patients.
Hiratsuka Site, Kanagawa prefecture
The Hiratsuka site leads research on manufacturing process development and quality evaluation of APIs and drug products to ensure high-quality new drugs can be stably delivered to patients, and deals with regulatory affairs with regulatory authorities on manufacturing and quality.
Daiichi Sankyo Pharma Development/Daiichi Sankyo, Inc., New Jersey, USA
Daiichi Sankyo Pharma Development (DSPD) leads planning, strategies, and operations for global clinical development in collaboration with the clinical development in Japan and related global departments.
Tissue & Cell Research Center, Munich, Germany
Together with the members of the research department of the Shinagawa R&D Center, we mainly conduct pharmacokinetic tests studies and translational research using human tissues.
Plexxikon Inc., Berkley, California, USA
From research to early phase of development, Plexxikon is advancing research and development with the focus on the field of oncology with highly original technology and management.
Development departments set up in five countries in Asia are leading the implementation of clinical development in Asian countries in global development in collaboration with R&D bases in Japan and the United States.
- Daiichi Sankyo (China) Holding Co., Ltd.
- Daiichi Sankyo Hong Kong Ltd.
- Daiichi Sankyo Taiwan Ltd.
- Daiichi Sankyo Korea Co., Ltd.
- Daiichi Sankyo (Thailand) Ltd.
Decision-making and effective resource allocation based on our science and global vision
GEMRAD (Global Executive Meeting of Research and Development), the highest decision-making body in R&D, consists of members of a wide range of specialized functions not only research and development but also pharmaceutical technology, biologics, medical affairs, safety assurance, marketing, business development, finance, to make comprehensive decisions effectively and efficiently allocating resources. GEMRAD actively delegates authority to global and cross-functional project teams for the purpose to speed up decision-making and implement high-quality project managements.
The project teams listen to the voices of medical practitioners and patients and actively discuss how our Science and Technology can meet medical needs from the early research stage. We are seamlessly nurturing creation of medicines throughout non-clinical stage to clinical stage. Our daily efforts, in which the project team takes the initiative and collaborates quickly, support our drug discovery activities.